Baxter to tackle rarer form of hemophilia

  Baxter International Inc., which sells one of the world's leading clotting drugs for the most common   form of    hemophilia, said Monday it has signed a deal with a California-based biotech company to begin early    research into a treatment for a  rarer form of the blood disorder.

  The Deerfield-based medical products giant said it has begun preclinical work in hopes of developing a    genetically engineered therapy for bleeding in patients with hemophilia B, which is caused by a genetic    mutation of the Factor IX gene.

  More than 750 ARH nurses strike

  More than 750 nurses at nine hospitals in Eastern Kentucky and West Virginia dropped their  stethoscopes   and walked out at 12:01 a.m. today after negotiations over a new contract with  Appalachian Regional   Healthcare stalled last week.

  Pat Tanner, a negotiator with the West Virginia and Kentucky Nurses Associations, said late last night   that   efforts to bring the not-for-profit hospital chain back to the bargaining table Saturday failed,  and that  without   a new contract, the nurses were prepared to go on strike after midnight.

  Hospital Faces Three Lawsuits Over Cadaver Tissue

  Bloomington Hospital now faces its third lawsuit filed by a patient upset by possibility they received   tainted    tissue from human cadavers during surgery.

   Lilly gets FDA nod for once-a-day Cialis

  Drug maker Eli Lilly and Co. has received FDA approval to offer its erectile dysfunction drug, Cialis,   in a new    daily dose.